Provided by Tiger Trade Technology Pte. Ltd.

MannKind

2.82
+0.21008.05%
Post-market: 2.820.0005+0.02%19:55 EDT
Volume:7.29M
Turnover:20.38M
Market Cap:865.94M
PE:141.00
High:2.92
Open:2.81
Low:2.72
Close:2.61
52wk High:6.51
52wk Low:2.52
Shares:307.07M
Float Shares:300.98M
Volume Ratio:1.06
T/O Rate:2.42%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.0200
EPS(LYR):0.0200
ROE:32.74%
ROA:4.91%
PB:-16.97
PE(LYR):141.00

Loading ...

MannKind Q4 revenue rises 46% as Furoscix sales surge

Reuters
·
Feb 26

MannKind Q4 revenue USD 112M +46%

Reuters
·
Feb 26

MannKind Q4 Adj. EPS $0.01, Inline, Sales $111.955M Beat $97.604M Estimate

Benzinga
·
Feb 26

BRIEF-MannKind Q4 Net Income USD -15.948 Million

Reuters
·
Feb 26

MannKind Q4 Total Revenue USD 112 Million VS. Ibes Estimate USD 97.6 Million

THOMSON REUTERS
·
Feb 26

MannKind Q4 Pretax Profit USD -20.931 Million

THOMSON REUTERS
·
Feb 26

Today’s Market Recap: AI Momentum Lifts U.S. Markets as Tariff Battles and Global Trade Tensions Unfold

TradingKey
·
Feb 26

RBC says United Therapeutics TreSMI presents ‘material risk’ to MannKind

TIPRANKS
·
Feb 26

Leerink sees MannKind selloff as ‘overreaction’ to headline news

TIPRANKS
·
Feb 26

MannKind Price Target Maintained With a $11.00/Share by HC Wainwright & Co.

Dow Jones
·
Feb 26

H.C. Wainwright sees MannKind selloff ‘potentially resetting’ value proposition

TIPRANKS
·
Feb 26

MannKind Down Over 35%, on Pace for Largest Percent Decrease Since January 2016 -- Data Talk

Dow Jones
·
Feb 26

MannKind sinks after United Therapeutics announces soft-mist inhaler

TIPRANKS
·
Feb 26

MannKind CEO Michael Castagna to Present at Oppenheimer Healthcare Life Sciences Conference

Reuters
·
Feb 19

MannKind Corporation Schedules Webcast to Review Financial Results and Business Update

Reuters
·
Feb 18

MannKind to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

GlobeNewswire
·
Feb 18

MannKind’s Pediatric Afrezza Trial Puts Needle Free Insulin Thesis To Test

Simply Wall St.
·
Feb 16

MannKind: Pediatric Expansion, Improved Dosing, and Pipeline Diversification Drive Buy Rating on Afrezza Growth Potential

TIPRANKS
·
Feb 10

BRIEF-Mannkind Announces First Patient Enrolled In Inhale-1St Pediatric Study Evaluating Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes (T1d)

Reuters
·
Feb 09

MannKind says first patient enrolled in INHALE-1ST study of Afrezza

TIPRANKS
·
Feb 09